Exosomes in Dermatology: Emerging Adjuncts With Uncertain Standardization

Key Takeaways

• A new paper xosomes are emerging as acellular signaling therapeutics with broad dermatologic and regenerative applications.
• Early clinical data suggest safety and potential benefit, particularly as adjuncts to procedures like microneedling and lasers.
• Standardization, regulatory clarity, and long-term data remain key barriers to mainstream adoption.

A recent narrative  synthesized evidence from 2020 to 2025 on exosome-based therapeutics, highlighting their expanding role in dermatology and regenerative medicine.

Across dermatologic applications, the authors wrote, preclinical models demonstrated that exosomes influence inflammation, angiogenesis, extracellular matrix remodeling, pigmentation pathways, and hair follicle cycling. Reported outcomes include accelerated wound healing, improved scar quality, attenuation of photoaging changes, and stimulation of hair growth. Additional exploratory signals have been described in inflammatory dermatoses and fungal skin conditions.

Early human studies, while limited, suggested acceptable safety profiles and a trend toward clinical benefit in wound care, scar revision, skin rejuvenation, and alopecia. Notably, exosomes are frequently used as adjunctive therapies alongside microneedling, laser treatments, or standard wound dressings. They did note that variability in product sourcing, dosing strategies and outcome measures complicates interpretation and comparison across studies.

Beyond dermatology, early investigations in musculoskeletal and soft tissue repair suggest regenerative potential, though clinical development remains preliminary. In current practice, exosomes are being positioned as alternatives or complements to platelet-rich plasma, bone marrow aspirate concentrate, and topical therapies, as well as potential delivery vehicles for biologics.

Key limitations include low manufacturing yields, cargo heterogeneity, lack of standardized potency assays, and unclear regulatory frameworks. 

"Overall, exosome therapies are still in their early stage, [and] basic questions about product identity, potency, and dosing are only beginning to be answered," the authors wrote. "Most available studies are small or uncontrolled. Yet the same features that make exosomes biologically attractive in the lab could eventually make them useful in the clinic. As manufacturing becomes more consistent and comparative trials accumulate, it should be possible to define where exosomes genuinely add value alongside or beyond existing options such as PRP, HA, and energy-based procedures. Until then, they are best regarded as investigational tools with promise rather than established treatments."

Source: Pham G. Biomedicines. 2026. Doi:10.3390/biomedicines14020338